Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence

@article{Cooper2006ContinuousTO,
  title={Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence},
  author={Brian T. Cooper and W H Chapman and C. S. Neumann and J C Gearty},
  journal={Alimentary Pharmacology \& Therapeutics},
  year={2006},
  volume={23}
}
There is little evidence that treatment of patients with Barrett's oesophagus with proton pump inhibitors over periods up to 6 years results in major regression of Barrett's oesophagus. 

Proton pump inhibitor use may not prevent high‐grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients

Proton pump inhibitors (PPI) may potentially modify and decrease the risk for development of oesophageal adenocarcinoma in Barrett's oesophagus (BO).

Influence of Long-Term Use of Proton Pump Inhibitors on Esophageal and Gastrointestinal Precancerous Lesions or Carcinoma

Patients with GERD and Barrett’s oesophagus should be encouraged to continue long term use of PPI therapy as a preventive measures for oesophageal adenocarcinoma.

Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma

Oesophageal adenocarcinoma is an increasingly common cancer with a poor prognosis. It develops in a stepwise progression from Barrett’s metaplasia to dysplasia, and then adenocarcinoma followed by

One year treatment of Barrett's oesophagus with proton pump inhibitors (a multi-center study).

Investigation of the effects of 1-year therapy by different proton pump inhibitors on epithelial tissue and surrounding inflammatory changes in Barrett's oesophagus in patients who have abandoned invasive therapy found no difference in regenerating squamous epithelium or degree of dysplasia.

One year treatment of Barrett’s oesophagus with proton pump inhibitors (a multi-center study)

Investigating the effects of 1-year therapy by different proton pump inhibitors on epithelial tissue and surrounding inflammatory changes in Barrett’s oesophagus found regeneration of the squamous epithel was the same for all PPIs but not good enough to stop the progression of the disease.

Barrett esophagus: Definition, treatment

  • S. Lai
  • Medicine
    Cleveland Clinic Journal of Medicine
  • 2020
To the Editor : In a well-written and informative article in the November 2019 issue, Singh et al reviewed the current management of Barrett esophagus and esophageal adenocarcinoma.[1][1] Here, I

Treatment of Barrett ’ s esophagus

The development of therapeutic endoscopy can now offer an effective alternative to esophagectomy in Barrett patients with high-grade dysplasia or early carcinoma. Endoscopic treatment has to be

The effects of high‐dose esomeprazole on gastric and oesophageal acid exposure and molecular markers in Barrett’s oesophagus

Aliment Pharmacol Ther 2010; 32: 1023–1030

Barrett's esophagus: endoscopic treatments I

Commentaries on indications for endoscopic treatments; endo‐luminal plication procedures; the cellular modifications induced by the endoscopic ablation therapies; eradication by banding without resection; and nondysplastic Barrett's esophagus are included.
...

References

SHOWING 1-10 OF 60 REFERENCES

Proton‐pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus

Whether proton‐pump inhibitor (PPI) therapy influences the incidence and progression of dysplasia in patients with Barrett's oesophagus is examined.

Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett’s oesophagus

Because of the malignant potential of Barrett’s oesophagus, an aim of treatment is to cause the columnar epithelium to regress. A logical approach is to decrease acid reflux which is an important

Long term continuous omeprazole treatment of patients with Barrett's oesophagus

The metaplastic columnar epithelium in Barrett's oesophagus has malignant potential and should be treated with chemotherapy, according to the World Health Organization.

Regression of columnar‐lined (Barrett’s) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy

The effect of 2’years of omeprazole 40’mg daily on columnar‐lined (Barrett’s) oesophagus (CLO) is reported.

Maximal acid reflux control for Barrett’s oesophagus: feasible and effective

The treatment of patients with Barrett’s oesophagus is controversial. Debate exists regarding the use and value of high dose acid suppression as the standard of practice. Despite prolonged use of

Review article: management of oesophageal adenocarcinoma — control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus

There is a great need for randomized controlled trials to assess the outcomes of such chemopreventive therapy in patients with Barrett's metaplasia and the effect of proton pump inhibitor therapy on cancer risk in the long term is essentially unknown.

The spectrum of columnar-lined esophagus--Barrett's esophagus.

Definition, developpement, aspects endoscopiques de l'œsophage de Barrett. Formation de polypes adenomateux et association a l'epithelioma glandulaire

Barrett’s oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?

There is overlap between the amount of acid exposure in patients with oesophagitis compared with patients with Barrett’s Oesophagus, suggesting that factors other than acid may be important in the aberrant oESophageal cell differentiation process that leads to the development of the metaplastic Barrett's mucosa.

Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study

Profound suppression of acid secretion, leading to elimination of acid reflux, induces partial regression of Barrett’s oesophagus.

[Barrett's esophagus].

Barrett's esophagus is a pre-malignant change in esophageal mucosa and the origin of adenocarcinoma and ablation of epithelium in combination with a subsequent long-term antisecretory therapy appears to be a promising treatment.
...